Innate Pharma announces trading halt of its ordinary shares on Euronext Paris
October 17, 2019INNATE PHARMA S.A. (la « Société » - Euronext Paris : FR0010331421 – IPH), société de biotechnologie française spécialisée dans la découverte, le développement et la commercialisation d’anticorps...Innate Pharma announces the pricing of its initial public offering on the Nasdaq global select market
October 17, 2019INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate Pharma ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-...Innate Pharma announces launch of proposed global offering and Nasdaq listing
October 7, 2019INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...Innate Pharma announces publication of a review article in Nature
October 3, 2019The authors present an updated version of The Cancer-Immunity Cycle 1 , the current intellectual framework for immuno-oncology research and development Article covers the mechanisms by which innate...Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
October 1, 2019IPH5401 dose-escalation study in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with secondary...Monalizumab to advance to Phase III in head and neck cancer
September 26, 2019Innate Pharma SA (the “Company” or “Innate” - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (LSE/STO/NYSE: AZN) will advance monalizumab into a Phase III randomized clinical...
